Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2026-04-29

Silk Road Medical (SILK)

CEO Chas McKhann was paid $13,423,834 in fiscal year 2023, the 99th percentile of its disclosed peer group (SEC filing 0001397702-24-000024 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$13,423,834
Chas McKhann total, FY2023
99th
CEO pay percentile vs peers
87:1
CEO-to-median pay ratio
82.38%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Chas McKhann$105,871$100,000$13,123,059$0$93,275$0$1,629$13,423,834
Chief Executive Officer
Erica Rogers628,67205,339,3321,515,898559,6500116,3528,159,904
Former President and Chief Executive Officer
Lucas Buchanan506,50005,788,0730307,377022,9936,624,943
Chief Operating Officer and Chief Financial Officer
Andrew Davis476,667400,0003,670,9320289,296029,7454,866,640
Chief Commercial Officer
Kevin Klemz430,00002,970,2960222,139013,2003,635,635
Executive Vice President, Chief Legal Officer and Secretary
Richard Ruedy345,83301,489,0260120,54109,9001,965,300
Executive Vice President of Regulatory and Clinical Affairs and Quality Assurance

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Chas McKhann$13,423,834———
Erica Rogers8,159,90415,277,0733,315,913↓ −7,117,169
Lucas Buchanan6,624,9439,559,0682,002,733↓ −2,934,125
Andrew Davis4,866,6407,897,9223,989,680↓ −3,031,282
Kevin Klemz3,635,6352,376,507—↑ +1,259,128
Richard Ruedy1,965,3001,501,138912,704↑ +464,162

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Silk Road Medical's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SILK reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against SILK
6 companies name SILK as a compensation peer

The list of companies that name SILK as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Donald J. ZurbayIndependent Director$228,135
Elizabeth H. WeathermanIndependent Director$212,488
Jack W. LasersohnChair of the Board$263,489
Kevin J. BallingerIndependent Director$220,473
Rick D. AndersonIndependent Director$221,311
Tanisha V. Carino, Ph.DIndependent Director$207,471
Tony M. Chou, M.DIndependent Director$202,471
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Andrew DavisChief Commercial Officer2024-05-20A2,000$7$14,100CommonForm 4 ↗
Kevin J. BallingerDirector2024-06-18A5,85900CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-06-18A5,85900CommonForm 4 ↗
Jack W. LasersohnDirector2024-06-18A5,85900CommonForm 4 ↗
Tanisha CarinoDirector2024-06-18A5,85900CommonForm 4 ↗
Tony M. ChouDirector2024-06-18A5,85900CommonForm 4 ↗
Donald J. ZurbayDirector2024-06-18A5,85900CommonForm 4 ↗
Rick D. AndersonDirector2024-06-18A5,85900CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-07-03D66271,782CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-08-19D2,2682761,470CommonForm 4 ↗
Dividend-equivalent accruals2024-09-17—4—~771 insider, 1 accrual row
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D28,88823657,780Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D25,92526671,458Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D205,711——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D70——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17A26,25000CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D5,331839,983Derivative, Class A CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D13,518——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17A50,87600CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D29,20615448,312Derivative, Class A CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D146,031213,123,603Derivative, Class A CommonForm 4 ↗
Kevin J. BallingerDirector2024-09-17D23,666——CommonForm 4 ↗
Chas McKhannDirector2024-09-17D1,299,042——CommonForm 4 ↗
Chas McKhannDirector2024-09-17A1,299,04200CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D62,958231,433,554Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D22,03326570,655Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D42,218——CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17D29,062——CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17D162,926——CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D12,610——CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D155,004——CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D290,077——CommonForm 4 ↗
Chas McKhannDirector2024-09-17D722,396——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D50,876——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D503,295——CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D33,2208249,150Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D1,8532139,636Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17A42,21800CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17A29,06200CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D16,51821353,320Derivative, Class A CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D71,661211,532,829Derivative, Class A CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D79,266——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D90,7408680,550Derivative, Class A CommonForm 4 ↗
Rick D. AndersonDirector2024-09-17D11,966——CommonForm 4 ↗
Tanisha CarinoDirector2024-09-17D11,396——CommonForm 4 ↗
Tony M. ChouDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Tony M. ChouDirector2024-09-17D85,251——CommonForm 4 ↗
Jack W. LasersohnDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Jack W. LasersohnDirector2024-09-17D16,735——CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D35,18526911,292Derivative, Class A CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D26,250——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 53 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Andrew DavisChief Commercial Officer2024-05-20A2,000$7$14,100CommonForm 4 ↗
Kevin J. BallingerDirector2024-06-18A5,85900CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-06-18A5,85900CommonForm 4 ↗
Jack W. LasersohnDirector2024-06-18A5,85900CommonForm 4 ↗
Tanisha CarinoDirector2024-06-18A5,85900CommonForm 4 ↗
Tony M. ChouDirector2024-06-18A5,85900CommonForm 4 ↗
Donald J. ZurbayDirector2024-06-18A5,85900CommonForm 4 ↗
Rick D. AndersonDirector2024-06-18A5,85900CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-07-03D66271,782CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-08-19D2,2682761,470CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D41977Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D28,88823657,780Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D25,92526671,458Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D205,711——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D70——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17A26,25000CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D5,331839,983Derivative, Class A CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D13,518——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17A50,87600CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D29,20615448,312Derivative, Class A CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D146,031213,123,603Derivative, Class A CommonForm 4 ↗
Kevin J. BallingerDirector2024-09-17D23,666——CommonForm 4 ↗
Chas McKhannDirector2024-09-17D1,299,042——CommonForm 4 ↗
Chas McKhannDirector2024-09-17A1,299,04200CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D62,958231,433,554Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D22,03326570,655Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D42,218——CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17D29,062——CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17D162,926——CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D12,610——CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D155,004——CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D290,077——CommonForm 4 ↗
Chas McKhannDirector2024-09-17D722,396——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D50,876——CommonForm 4 ↗
Lucas BuchananCOO & CFO2024-09-17D503,295——CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D33,2208249,150Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17D1,8532139,636Derivative, Class A CommonForm 4 ↗
Andrew DavisChief Commercial Officer2024-09-17A42,21800CommonForm 4 ↗
Kevin KlemzEVP/Chief Legal Officer/Sec.2024-09-17A29,06200CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D16,51821353,320Derivative, Class A CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D71,661211,532,829Derivative, Class A CommonForm 4 ↗
Marie L. JonesVP, Finance and CAO2024-09-17D79,266——CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D90,7408680,550Derivative, Class A CommonForm 4 ↗
Rick D. AndersonDirector2024-09-17D11,966——CommonForm 4 ↗
Tanisha CarinoDirector2024-09-17D11,396——CommonForm 4 ↗
Tony M. ChouDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Tony M. ChouDirector2024-09-17D85,251——CommonForm 4 ↗
Jack W. LasersohnDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Jack W. LasersohnDirector2024-09-17D16,735——CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Elizabeth H. WeathermanDirector2024-09-17D35,18526911,292Derivative, Class A CommonForm 4 ↗
Donald J. ZurbayDirector2024-09-17D8,910866,825Derivative, Class A CommonForm 4 ↗
Richard RuedyEVPClin&Reg.Affairs&QA2024-09-17D26,250——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Richard RuedyPSU2023-03-021,4135,654—11,308$392,388
Chas McKhannPSU2023-11-02153,020612,083—1,224,1668,055,012
Lucas BuchananPSU2023-03-022,82711,308—22,616784,775
Erica RogersPSU2023-03-0210,13040,520—81,0402,812,088
Andrew DavisPSU2023-03-022,2619,046—18,092627,792
Andrew DavisRSU2023-09-15——121,519—2,056,101
Lucas BuchananRSU2023-09-15——121,519—2,056,101
Lucas BuchananRSU2023-09-15——101,266—1,713,421
Kevin KlemzPSU2023-03-022,1208,481—16,962588,581
Kevin KlemzRSU2023-09-15——86,076—1,456,406
Richard RuedyRSU2023-09-15——28,354—479,750
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Richard Ruedy$479,750$392,388$045.0%
Chas McKhann08,055,0120100.0%
Lucas Buchanan3,769,522784,775017.2%
Erica Rogers02,812,0880100.0%
Andrew Davis2,056,101627,792023.4%
Kevin Klemz1,456,406588,581028.8%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Chas McKhannRSU612,083—$7,510,258
Lucas BuchananOption2,01130.93—
Richard RuedyOption9,20937.07—
Lucas BuchananRSU26,925—330,370
Lucas BuchananPSU2,827—34,687
Andrew DavisPSU17,289—212,136
Andrew DavisPSU2,261—27,742
Lucas BuchananOption18,41737.07—
Kevin KlemzRSU86,076—1,056,153
Richard RuedyPSU1,413—17,338
Andrew DavisOption2,01130.93—
Richard RuedyOption2,87555.3—
Andrew DavisOption17,86037.07—
Lucas BuchananOption9,78169.94—
Andrew DavisRSU21,346—261,915
Andrew DavisRSU225—2,761
Lucas BuchananOption7,50055.3—
Lucas BuchananRSU101,266—1,242,534
Richard RuedyRSU28,354—347,904
Erica RogersOption47,99336.01—
Lucas BuchananRSU5,374—65,939
Lucas BuchananRSU121,519—1,491,038
Richard RuedyOption1,43530.93—
Kevin KlemzRSU15,244—187,044
Andrew DavisRSU26,115—320,431
Chas McKhannPSU153,020—1,877,555
Richard RuedyRSU13,341—163,694
Andrew DavisRSU121,519—1,491,038
Lucas BuchananRSU26,682—327,388
Kevin KlemzRSU20,011—245,535
Erica RogersOption5,74730.93—
Lucas BuchananOption15,07037.07—
Lucas BuchananRSU22,035—270,369
Lucas BuchananPSU17,289—212,136
Richard RuedyRSU13,463—165,191
Richard RuedyRSU2,150—26,381
Kevin KlemzOption26,36049.2—
Andrew DavisRSU5,650—69,326
Lucas BuchananRSU5,650—49,326
Kevin KlemzPSU2,120—26,012
Lucas BuchananRSU1,169—14,344
Andrew DavisRSU1,169—14,344
Richard RuedyRSU838—10,282
Erica RogersOption14,40755.3—
Erica RogersOption91,51936.01—
Andrew DavisOption89052.07—
Andrew DavisOption7,50055.3—
05

Incentive-plan design — the Compensation Discussion & Analysis

We have designed our executive compensation program to reward our executives at a level consistent with our overall strategic and financial performance and to provide remuneration sufficient to attract, retain, and motivate them. We believe that competitive compensation packages consisting of a combination of base salaries, annual bonus opportunities, and long-term incentive opportunities in the form of equity awards enable us to attract top talent, motivate successful short-term and long-term performance, and align the compensation of our executives with our performance and long-term value creation for our stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantCompensia, Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-1824,560,7595,253,5331,263,14582.38%Passed
20232023-06-2113,904,62620,247,58925,36740.71%Failed
20222022-06-0926,863,5684,646,83548,97685.25%Passed
20212021-06-1726,610,5644,364,67212,32485.91%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-1882.38%a
20232023-06-2140.71%b
20222022-06-0985.25%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)87 : 1
CEO total compensation—
Median employee compensation$176,552
08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jack W. LasersohnIndependent · Board Chair · Audit · Nominating and Corporate Governance$103,658$157,477$2,354——$263,489
Donald J. ZurbayIndependent · Audit (Chair) · Compensation70,658157,4770—0228,135
Rick D. AndersonIndependent · Compensation (Chair) · Nominating and Corporate Governance62,658157,4771,176——221,311
Kevin J. BallingerIndependent · Audit · Compensation60,658157,4772,338——220,473
Elizabeth H. WeathermanIndependent · Nominating and Corporate Governance (Chair)52,658157,4772,353——212,488
Tanisha V. Carino, Ph.DIndependent · Nominating and Corporate Governance47,658157,4772,336——207,471
Tony M. Chou, M.DIndependent42,658157,4772,336——202,471
Chas S. McKhannEmployee director · Partial-year service—————0
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$157,500
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$440,606
Equity awards (grant-date value)$1,102,339
All other compensation$0
Total cost of the board$1,542,945

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Silk Road Medical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Silk Road Medical.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Silk Road Medical2023Chas McKhann$105,871$13,123,059$0$93,275$13,423,834
2Glaukos Corporation2025Thomas Burns850,0007,649,9473,527,497012,034,087
3Alphatec Holdings, Inc.2025Patrick Miles762,0008,859,6500600,00010,260,507
4AtriCure, Inc.2025Michael Carrel828,4397,203,47801,171,7039,217,620
5Inari Medical, Inc.2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
6Outset Medical, Inc.2025Leslie Trigg755,1662,197,8820294,5153,255,510

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Silk Road Medicalnot disclosedPSU 50 · RSU 50Yes — Total Stockholder Return (TSR) relative to peer groupCompensia, Inc.
Alphatec Holdings, Inc.157%PSU 50 · RSU 50NoCompensia
AtriCure, Inc.141%PSU 70 · RSU 30NoKorn Ferry
Glaukos Corporation177.5%RSU 50 · PRSU 50NoFrederic W. Cook & Co., Inc.
Inari Medical, Inc.118%RSU 75 · Option 25not disclosedFW Cook
Outset Medical, Inc.39%PSU 50 · RSU 50Yes — Relative TSR compared to Russell 2000 Medical Device IndexPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Silk Road Medical in fiscal 2023?
As disclosed, Chas McKhann (Chief Executive Officer) was the highest-paid executive at Silk Road Medical in fiscal 2023, with total compensation of $13,423,834.
How does Silk Road Medical's chief executive pay compare to its disclosed peer group?
As disclosed, Chas McKhann's total compensation ranked at the 99th percentile of Silk Road Medical's disclosed peer group.
What is Silk Road Medical's CEO-to-median employee pay ratio?
As disclosed, Silk Road Medical's CEO-to-median employee pay ratio was 87:1.
How did shareholders vote on Silk Road Medical's executive compensation?
As disclosed, 82.38% of shareholders supported Silk Road Medical's executive compensation in the latest say-on-pay vote.
How much does Silk Road Medical spend in total on board compensation for fiscal 2023?
As disclosed, Silk Road Medical reported total board compensation of $1,542,945 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Chas McKhannDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706
2Section 01, Erica RogersDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 8,159,904. Filing ↗machine: r4 · c8 · span 1766669–1766678
3Section 01, Lucas BuchananDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 6,624,943. Filing ↗machine: r7 · c8 · span 1782333–1782342
4Section 01, Andrew DavisDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 4,866,640. Filing ↗machine: r10 · c8 · span 1798173–1798182
5Section 01, Kevin KlemzDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 3,635,635. Filing ↗machine: r13 · c8 · span 1813380–1813389
6Section 01, Richard RuedyDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation”. As printed: 1,965,300. Filing ↗machine: r16 · c8 · span 1829226–1829235
7Section 03, Richard Ruedy PSUDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
8Section 03, Chas McKhann PSUDEF 14A2024-04-260001397702-24-000024Section “GRANTS OF PLAN-BASED AWARDS DURING 2023” · grants of plan-based awards table. Filing ↗machine: t92 · r4 · c9 · span 1939091–1939100
9Section 03, Lucas Buchanan PSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r8 · c9 · span 1967094–1967101
10Section 03, Erica Rogers PSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r6 · c9 · span 1953220–1953229
11Section 03, Andrew Davis PSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r12 · c9 · span 1992251–1992258
12Section 03, Andrew Davis RSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t82 · r5 · c1 · span 1615626–1615633
13Section 03, Lucas Buchanan RSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r9 · c9 · span 1972459–1972468
14Section 03, Lucas Buchanan RSUDEF 14A2024-04-260001397702-24-000024Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t92 · r10 · c9 · span 1978002–1978011
15Section 03, Kevin Klemz PSUDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
16Section 03, Kevin Klemz RSUDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
17Section 03, Richard Ruedy RSUDEF 14A2024-04-260001397702-24-000024Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
18Section 07, pay ratioDEF 14A2023-04-280001397702-23-000025Section “CEO Pay Ratio”. As printed: 87 : 1. Filing ↗machine: span 534087–534089
19Section 08, Jack W. LasersohnDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 263,489. Filing ↗machine: span 3269939–3270307
20Section 08, Donald J. ZurbayDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 228,135. Filing ↗machine: span 3276838–3277206
21Section 08, Rick D. AndersonDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 221,311. Filing ↗machine: span 3256325–3256693
22Section 08, Kevin J. BallingerDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 220,473. Filing ↗machine: span 3259658–3260026
23Section 08, Elizabeth H. WeathermanDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 212,488. Filing ↗machine: span 3273367–3273735
24Section 08, Tanisha V. Carino, Ph.DDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 207,471. Filing ↗machine: span 3263135–3263503
25Section 08, Tony M. Chou, M.DDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 202,471. Filing ↗machine: span 3266558–3266926
26Section 08, Chas S. McKhannDEF 14A2024-04-260001397702-24-000024Section “Director Compensation”. As printed: 0. Filing ↗
27Section 02, Andrew Davis 2024-05-20Form 42024-07-080001593968-24-000945Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Kevin J. Ballinger 2024-06-18Form 42024-06-210001593968-24-000882Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Elizabeth H. Weatherman 2024-06-18Form 42024-06-210001593968-24-000886Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jack W. Lasersohn 2024-06-18Form 42024-06-210001593968-24-000885Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Tanisha Carino 2024-06-18Form 42024-06-210001593968-24-000883Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Tony M. Chou 2024-06-18Form 42024-06-210001593968-24-000884Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Donald J. Zurbay 2024-06-18Form 42024-06-210001593968-24-000887Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Rick D. Anderson 2024-06-18Form 42024-06-210001593968-24-000889Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Andrew Davis 2024-07-03Form 42024-07-080001593968-24-000945Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Kevin Klemz 2024-08-19Form 42024-08-210001593968-24-001091Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Lucas Buchanan 2024-09-17Form 42024-09-180001140361-24-041408Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Lucas Buchanan 2024-09-17Form 42024-09-180001140361-24-041408Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Lucas Buchanan 2024-09-17Form 42024-09-180001140361-24-041408Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Donald J. Zurbay 2024-09-17Form 42024-09-180001140361-24-041431Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Donald J. Zurbay 2024-09-17Form 42024-09-180001140361-24-041431Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Kevin J. Ballinger 2024-09-17Form 42024-09-180001140361-24-041421Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Chas McKhann 2024-09-17Form 42024-09-180001140361-24-041406Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Chas McKhann 2024-09-17Form 42024-09-180001140361-24-041406Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kevin Klemz 2024-09-17Form 42024-09-180001140361-24-041412Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Kevin Klemz 2024-09-17Form 42024-09-180001140361-24-041412Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Donald J. Zurbay 2024-09-17Form 42024-09-180001140361-24-041431Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Elizabeth H. Weatherman 2024-09-17Form 42024-09-180001140361-24-041429Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Chas McKhann 2024-09-17Form 42024-09-180001140361-24-041406Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Lucas Buchanan 2024-09-17Form 42024-09-180001140361-24-041408Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Lucas Buchanan 2024-09-17Form 42024-09-180001140361-24-041408Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Andrew Davis 2024-09-17Form 42024-09-180001140361-24-041410Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Kevin Klemz 2024-09-17Form 42024-09-180001140361-24-041412Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Marie L. Jones 2024-09-17Form 42024-09-180001140361-24-041414Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Marie L. Jones 2024-09-17Form 42024-09-180001140361-24-041414Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Marie L. Jones 2024-09-17Form 42024-09-180001140361-24-041414Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Rick D. Anderson 2024-09-17Form 42024-09-180001140361-24-041419Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Tanisha Carino 2024-09-17Form 42024-09-180001140361-24-041423Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Tony M. Chou 2024-09-17Form 42024-09-180001140361-24-041425Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Tony M. Chou 2024-09-17Form 42024-09-180001140361-24-041425Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jack W. Lasersohn 2024-09-17Form 42024-09-180001140361-24-041427Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Jack W. Lasersohn 2024-09-17Form 42024-09-180001140361-24-041427Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Elizabeth H. Weatherman 2024-09-17Form 42024-09-180001140361-24-041429Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Elizabeth H. Weatherman 2024-09-17Form 42024-09-180001140361-24-041429Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Donald J. Zurbay 2024-09-17Form 42024-09-180001140361-24-041431Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Richard Ruedy 2024-09-17Form 42024-09-180001140361-24-041416Insider equity transaction reported since the proxy statement. Filing ↗
80Section 06, 2024 voteForm 8-K2024-06-200001397702-24-000040Item 5.07 · say-on-pay result. As reported: 82.38% (votes for as printed: 24,560,759). Filing ↗
81Section 06, 2023 voteForm 8-K2023-06-230001397702-23-000046Item 5.07 · say-on-pay result. As reported: 40.71% (votes for as printed: 13,904,626). Filing ↗
82Section 06, 2022 voteForm 8-K2022-06-100001397702-22-000037Item 5.07 · say-on-pay result. As reported: 85.25% (votes for as printed: 26,863,568). Filing ↗
83Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
84Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
85Section 09b board cost (computed)Computed——Cash 440,606 + equity 1,102,339 + all other 0 = 1,542,945, summed across the director compensation table rows.machine: formula: Σ = 1,542,945
86Silk Road Medical (subject), Section 10b CEO totalDEF 14A2024-04-260001397702-24-000024CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706
87Glaukos Corporation, Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952
88Alphatec Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-290001193125-26-191867CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158
89AtriCure, Inc., Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
90Inari Medical, Inc., Section 10b CEO totalDEF 14A2024-03-130001193125-24-066805CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517
91Outset Medical, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177150CEO total compensation as printed in Outset Medical, Inc.'s own proxy. As printed: 3,255,510. Filing ↗machine: r2 · c30 · span 1343364–1343373
92Section 10a, AtriCure, Inc. reciprocityDEF 14A—0001323885-26-000010AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗
93Section 10a, Alphatec Holdings, Inc. reciprocityDEF 14A—0001193125-26-191867Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗
94Section 10a, Glaukos Corporation reciprocityDEF 14A—0001193125-26-157829Glaukos Corporation's most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗
95Section 10a, Inari Medical, Inc. reciprocityDEF 14A—0001193125-24-066805Inari Medical, Inc. names Silk Road Medical in its own disclosed peer group (read from its most recent proxy). Filing ↗
96Section 10a, Outset Medical, Inc. reciprocityDEF 14A—0001193125-26-177150Outset Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Silk Road Medical. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.